Moderna shares are trading lower after the company revised its 2024 expectations citing low EU sales, potential revenue deferrals for certain international sales into 2025 and an 'increasingly competitive environment' for respiratory vaccines in the US.
Portfolio Pulse from Benzinga Newsdesk
Moderna shares are trading lower after the company revised its 2024 expectations due to low EU sales, potential revenue deferrals for certain international sales into 2025, and an increasingly competitive environment for respiratory vaccines in the US.
August 01, 2024 | 10:38 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Moderna shares are trading lower after the company revised its 2024 expectations due to low EU sales, potential revenue deferrals for certain international sales into 2025, and an increasingly competitive environment for respiratory vaccines in the US.
The revision of 2024 expectations by Moderna due to low EU sales, potential revenue deferrals, and increased competition in the US respiratory vaccine market is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100